ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

This trial tests a combination of ONC201 (a new investigational drug that targets specific proteins in cancer cells) plus weekly paclitaxel (a standard chemotherapy) for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemotherapy — called platinum-resistant or platinum-refractory disease. **You may be eligible if...** - You have ovarian, fallopian tube, or primary peritoneal cancer - Your cancer progressed within 6 months of completing platinum-based chemotherapy, or during platinum treatment - You have received no more than 4 prior treatment regimens in the platinum-resistant setting (up to 7 total) - You have at least one measurable tumor on imaging - You are in adequate general health **You may NOT be eligible if...** - Your cancer is platinum-sensitive (responded well and remained controlled for more than 6 months after platinum) - You have had more prior lines of therapy than allowed - You have severe neuropathy (nerve damage) - You are pregnant or breastfeeding - You have active uncontrolled infections or severe organ problems Talk to your doctor to see if this trial is right for you.